Luminopia's CEO says payer churn slows coverage and can require patching first
Luminopia co-founder and CEO Scott Xiao told HLTH's Partner Highlight series that short payer member tenure and a fragmented Medicaid leave pediatric amblyopia neglected. A 2025 JMCP payer roundtable recommended covering the FDA-authorized therapy but allowed step-edits, while PEDIG data show two-hour patching adds about 1.1 lines of acuity. Cleveland Clinic registry data report 1.8 lines of gain in severe cases.
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Key takeaways
A 2025 payer roundtable in the Journal of Managed Care & Specialty Pharmacy recommended plans cover Luminopia, yet said step-edits and letters of exception may still be required, with more than 9,000 prescriptions written since November 2022.
PEDIG's ATS05 trial put two hours of daily patching at 1.1 lines of gain over five weeks versus 0.5 lines for glasses alone, while a 2015 AAO review tied patching's poor compliance to social stigma.
S.1702, the Access to Prescription Digital Therapeutics Act of 2025, has sat in the Senate Finance Committee since May 8, 2025, leaving coverage negotiated plan by plan.
Free workspace
Turn your Healthcare expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
Scott Xiao came to HLTH's digital health and AI awards with a treatment that turns Sesame Street into a prescription, and he spent his segment on something less cheerful. Speaking in a MarketScale-produced HLTH Partner Highlight segment, the co-founder and CEO of Luminopia said the health care system systematically under-invests in children. The reason, he argued, is structural: the organizations paying for a child's care are built to think in short horizons.
Xiao argues private payers hold members too briefly to care about a child's vision decades out. Medicaid, in his telling, fares no better. For a pediatric ophthalmologist deciding what to prescribe, or a plan medical director deciding what to cover, that incentive gap is the difference between a 12-week headset course and months of eye patches.
The timing is not abstract. In April 2026 the Food and Drug Administration published the Federal Register rule that formally codifies the device class Luminopia created when it won de novo authorization in October 2021, and in December 2025 Cleveland Clinic reported that the authorized age range, originally 4 to 7, widened to include ages 8 to 12 during 2025. The product's regulatory footing has firmed up in the past year; what Xiao is describing is the lag on the payment side.
We have private insurance companies where the average tenure of each member may only be a couple of years, and these payers are incentivized not to think about benefits or cost savings of their members beyond that, again, disadvantages the pediatric population. — Scott Xiao, Co-founder & CEO, Luminopia
Short member tenure, long pediatric payoff
The mechanism Xiao describes is a timing mismatch. A plan pays for amblyopia treatment while the child is four, five or six years old. The avoided cost, a lifetime of impaired vision in one eye, shows up over decades, and if the family changes insurers the saving lands on someone else's books.
A 2025 payer roundtable in the Journal of Managed Care & Specialty Pharmacy tied traditional amblyopia treatment to permanent vision loss and excess health care use. The roundtable, which paired pediatric ophthalmologists with national and regional health plan leaders, also listed extended treatment periods and reduced quality of life for patients and caregivers as costs of the older approach. Those are the downstream costs a short-tenure member never generates for the plan that could have prevented them.
Xiao put it in investment terms. Early intervention, he said, is where any health care spend gets its highest return because it changes the trajectory of a life, and the system reaps the health and economic benefits for decades. The plan writing the check, by his account, has little reason to look that far.
Patching works, but only when kids wear it
Amblyopia, the clinical name for lazy eye, is a reduction in best-corrected visual acuity in an otherwise healthy eye, meaning the eye still sees poorly after the right glasses are on. The JMCP roundtable described the usual cause as abnormal processing of visual images rather than a structural defect, called it the most common cause of vision impairment in children, and put North American prevalence at 2% to 4%. Xiao's own scale is more vivid.
The standard treatment penalizes the stronger eye. A patch covers it for a set number of hours a day so the brain is forced to use the weaker one, and the results of that protocol are well documented.
In PEDIG's ATS05 trial, two hours of daily patching beat glasses alone by 0.6 lines at five weeks. The Pediatric Eye Disease Investigator Group, a research network whose trial records are hosted by the JAEB Center for Health Research, ran the multicenter trial from December 2003 to December 2005 in 180 children aged 3 to 7, and reported average gains of 1.1 lines with patching versus 0.5 lines with glasses alone at five weeks, and 2.2 versus 1.3 lines at best measured acuity. A line, in this context, is one row on an eye chart.
The same program found that glasses alone did much of the work. In PEDIG's results summary, 77% of children improved two or more lines on spectacles and amblyopia resolved in 27% before any patch was applied. The American Academy of Ophthalmology, in an October 2015 disease review by Rebecca S. Braverman, added that two hours a day works as well as six for moderate amblyopia, that 62% of patients reach 20/30 or gain at least three lines within about four months, and that six hours a day produced an average 4.1 lines of gain in severe cases.
That is the complication for anyone who hears patching dismissed outright: the protocol, when followed, is effective. Followed is the operative word. The same AAO review stated that social stigma around patching and the daily-life difficulties it creates lead to poor compliance and significant family dissatisfaction, which is the finding Xiao leans on.
The JMCP roundtable went further than compliance. Occluding the better eye addresses only the weak eye, the panel wrote, and does nothing for the binocular deficits of amblyopia, the two eyes' failure to work together, which in its account leaves most patients with unresolved disease.
How contrast-reduced Sesame Street retrains an eye
Luminopia's approach is dichoptic, meaning each eye is shown a different version of the same image. In a December 2025 report, Cleveland Clinic's Consult QD described the device as a virtual reality headset that plays popular television content with the contrast turned down for the healthy eye, so the amblyopic eye has to compensate to assemble the picture. The randomized trial Cleveland Clinic cited ran one hour a day, six days a week, for 12 weeks.
The regulatory path was de novo, the FDA pathway for a novel device with no existing category to compare against. The classification was applicable on October 20, 2021, according to a Federal Register rule the FDA published on April 22, 2026, under docket FDA-2026-N-3928, which places the digital therapy device for amblyopia in 21 CFR part 882. The JMCP paper gave the original indication as amblyopia associated with anisometropia, an unequal prescription between the two eyes, and/or mild strabismus, a misalignment of the eyes, in children aged 4 to 7.
The American Academy of Ophthalmology added binocular digital therapy to its Amblyopia Preferred Practice Pattern as of February 2024, according to the JMCP paper, and recognized Luminopia's phase 3 randomized controlled trial as Level I+ evidence, the rating the Academy assigns to well-designed randomized trials. An October 2023 analysis in the Journal of AAPOS, posted to the National Institutes of Health's PubMed Central archive, pooled 121 children from two open-label pilot studies and the randomized trial to identify which factors predicted a visual acuity response.
Cleveland Clinic registry patients with 20/100 or worse vision gained a mean 1.8 lines on Luminopia over 11.8 months. That figure comes from a review of 59 patients, mean age 7.8, drawn from the Patients Using Prescription Luminopia registry of more than 500 users, presented by Cleveland Clinic pediatric optometrist Alexandra Williamson at the 2025 American Academy of Optometry meeting. Patients averaged 163 treatment hours, 46% improved two lines or more, and the nine legally blind patients at 20/200 or worse averaged 2.8 lines over 15.7 months.
Two factors in that review matter for a prescriber. Treatment-naive patients gained 3.8 lines against 1.5 lines for those with prior amblyopia treatment, and more treatment hours tracked with more improvement. A reader tempted to set the 1.8-line registry figure beside PEDIG's 2.2-line patching result should resist: the populations, severities, ages and durations differ, and neither study placed the two therapies against each other.
Covered on paper, step-edited in practice
Pediatric ophthalmologists and plan leaders recommended Luminopia for coverage in 2025 yet allowed step-edits requiring documented failure of other therapies. A step-edit is a plan rule that a cheaper or older treatment must be tried first, and the JMCP roundtable said plans may use one, may require documentation of inadequate response to other therapies, and may require clinical documentation plus a medical letter of exception for off-label use. The panel also said the therapy may sit under either the medical or the pharmacy benefit, with duration left to the prescribing physician.
The roundtable put the commercial picture in numbers. More than 9,000 prescriptions had been written by more than 1,000 prescribers since Luminopia became commercially available in November 2022, the paper reported, and coverage at that point included a medical policy at one large national health plan plus inclusion on many regional plan formularies. Neither the roundtable paper nor Xiao's segment names that national plan, lists billing codes or gives a price.
For a practice, the operational meaning is that an FDA-authorized, guideline-listed therapy can still require a patching trial on the record before a plan pays. That is the adoption friction Xiao attributes to incentives: by the roundtable's own account the clinical recommendation was unanimous and the coverage recommendation was broad, yet the recommended policy design still builds in a hurdle.
Medicaid cuts and a stalled federal bill
Xiao's second structural claim is about Medicaid, which he called the main government payer for children, chronically underfunded and too fragmented administratively to plan for the long term. Medicaid is run state by state, which is what fragmentation means in practice, and each state sets rates on its own budget calendar.
Colorado Medicaid rolled back a 1.6% rate increase for dates of service from October 1, 2025. The Colorado Department of Health Care Policy & Financing said in a September 2025 provider bulletin that Governor Polis issued Executive Order D 2025 014 on August 28, 2025, ordering suspensions of certain programs to balance the fiscal year 2025-26 budget, and that the department would reduce all fee-for-service rates it had raised 1.6% through legislative appropriations. Dental, some home and community-based services and pediatric behavioral therapies were targeted for deeper cuts; the group adaptive behavior treatment code 97154 went from $11.51 to $8.81, a 23% reduction by arithmetic on the bulletin's figures.
The bulletin says nothing about Luminopia or amblyopia. It shows the pattern Xiao describes: a pediatric service line priced by one state's revenue forecast, revised within a quarter, with no mechanism that weighs a child's outcome decades later.
At the federal level the gap is written into pending legislation. Senator Shelley Moore Capito introduced S.1702, the Access to Prescription Digital Therapeutics Act of 2025, on May 8, 2025, according to Congress.gov, and the bill was read twice and referred to the Senate Finance Committee the same day, where its listed status remains. The Congressional Research Service summary says the bill would provide Medicare and Medicaid coverage of prescription digital therapeutics, software applications used to prevent, manage or treat medical conditions, and would require the Centers for Medicare & Medicaid Services to set a Medicare payment methodology that accounts for factors such as ongoing use.
This is where Xiao's incentive argument reaches past Luminopia. The bill also requires manufacturers to report specified information about private payors, subject to civil penalties, which tells the reader that Congress treats private coverage of the whole prescription digital therapeutic category as something it cannot currently see. With no payment methodology in statute, each manufacturer negotiates plan by plan, and a pediatric product does so with a payer whose member may be gone before the benefit arrives.
Luminopia is not the only headset in the clinic
Cleveland Clinic names three binocular technologies, Luminopia, CureSight and Vivid Vision, with Vivid Vision not available in the US. In its December 2025 report, Cleveland Clinic described CureSight as a system in which the child wears red-blue filters while watching video on a portable screen, with eye tracking used to blur the image at the healthy eye's central fixation, and Vivid Vision as virtual reality games played through a head-mounted display. Williamson, who has prescribed both Luminopia and CureSight, said dichoptic therapies are more engaging for children and are producing good adherence and outcomes.
She also qualified it. Each child needs an individualized plan, dichoptic therapy may not suit everyone, and some patients do best on a mix of dichoptic and conventional treatment, she told Cleveland Clinic. The AAO review adds that atropine drops, which blur the good eye, match patching for moderate amblyopia and score better on quality of life, so the patch is not even the only conventional option.
Xiao's wager is narrower than being the sole alternative. It is that a treatment a child chooses to do will be completed, and that completion is what the AAO's compliance findings say the patch too often lacks. The registry correlation between treatment hours and improvement that Williamson's team reported is the kind of evidence that argument needs.
The marker the JMCP roundtable set is demand: as prescriptions climb, it wrote, coverage considerations become top of mind for payers, and its recommendation was framed as justification for broad coverage. Two signals would show whether the incentive gap Xiao describes is closing: the Senate Finance Committee acting on S.1702, which has no cost estimate listed and no recorded action since May 2025, and national plans writing Luminopia policies without the step-edit the roundtable allowed. Until one of those moves, the roundtable's own recommendations mean a prescriber should plan to document a patching trial before the first headset ships.
Sources
- S.1702 - Access to Prescription Digital Therapeutics Act of 2025 ↗ · Congress.gov / Library of Congress
- Medical Devices; Ophthalmic Devices; Classification of the Digital Therapy Device for Amblyopia ↗ · Federal Register / FDA
- Recommendations for use and coverage of digital, dual-acting therapy for amblyopia ↗ · Journal of Managed Care & Specialty Pharmacy
- Special Provider Bulletin - Rate Reductions 092025_B2500528 ↗ · Colorado Department of Health Care Policy & Financing
- Factors associated with visual acuity improvement with a binocular digital therapeutic for amblyopia ↗ · Journal of AAPOS (via PMC/NIH)
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
About the author
The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.